A review of aberrant DNA methylation and epigenetic agents targeting DNA methyltransferase in endometriosis.
Curr Drug Targets. 2020 Feb 27;:
Authors: Yang L, Ding L, Ren C, Zhang H, Lu J, Wang S, Wu Z, Yang Y
BACKGROUND: Endometriosis (EMs)is a gynecological disease defined by the endometrial tissue appearing in other tissues or organs outside the uterus. Its clinical manifestations are dysmenorrhea, irregular menstruation, even infertility. Although EMs is a benign disease, it has the characteristics of malignant tumor and has the potential of malignant transformation. Recent studies have found that endometriosis may involve epigenetic changes and various epigenetic aberrations may play an essential role in the pathogenesis of endometriosis. Among them, aberrant DNA methylation is the main form. Previous studies have elucidated the epigenetic components of endometriosis and reported variations in epigenetic patterns of genes known to be associated with abnormal hormonal, immune, and inflammatory states of endometriosis. With the development of high-throughput sequencing and other biomolecular technologies，we have a better understanding of genome-wide methylation in endometriosis.
OBJECTIVE: But the epigenetic drugs targeting of DNA methylation in the therapy of endometriosis hasn’t been elaborated systematically.
RESULTS: This article review the role of DNA methylation in the pathophysiology of endometriosis and provide the insight into the mechanisms underlining the potential application of targeting of DNA methylation modifiers as a novel therapeutic approach for endometriosis. We also review current progress in using DNA methylation inhibitors in EMs therapy and the potential promise and challenges ahead.
CONCLUSION: Aberrant DNA methylation plays an essential role in the pathogenesis of endometriosis and epigenetic agents targeting DNA methyltransferase is expected to be the theoretical basis for the new treatment of endometriosis.
PMID: 32107990 [PubMed – as supplied by publisher]